[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100623654":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":24,"locations":33,"responsibleParty":128,"collaborators":130,"id":134,"slug":135,"hasResults":136,"nctId":137,"briefTitle":138,"officialTitle":139,"acronym":140,"eligibilityCriteria":141,"healthyVolunteers":136,"sex":142,"minAge":143,"maxAge":19,"enrollmentInfo":144,"targetDuration":19,"studyType":147,"phases":148,"briefSummary":150,"conditions":151,"keywords":153,"overallStatus":155,"whyStopped":19,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":157,"startDateStruct":160,"completionDateStruct":162,"leadSponsor":164,"locationsCount":165},{"fullName":5,"class":6},"Institute of Hematology & Blood Diseases Hospital, China","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"LVIVO-TaVec400 product","EXPERIMENTAL","Each subject will be given a single-dose LVIVO-TaVec400 product infusion at each dose level",[13],"Biological: LVIVO-TaVec400 product",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"BIOLOGICAL","Prior to infusion of the LVIVO-TaVec400 product, subjects will receive bridging therapy if needed.",[9],null,[21],{"name":22,"affiliation":5,"role":23},"Lugui Qiu","PRINCIPAL_INVESTIGATOR",[25,30],{"name":26,"role":27,"phone":28,"phoneExt":19,"email":29},"Gang An","CONTACT","+86 022-23909083","angang@ihcams.ac.cn",{"name":31,"role":27,"phone":19,"phoneExt":19,"email":32},"Jianling Yao","jianling.yao@legendbiotech.cn",[34,55,70,85,101,116],{"facility":35,"status":19,"city":36,"state":37,"zip":19,"country":38,"countryCode":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":46},"Henan Cancer Hospital","Zhengzhou","Henan","China","CN",{"type":41,"coordinates":42},"Point",[43,44],113.64861,34.75778,{"lat":44,"lon":43},[47,51,53],{"name":48,"role":27,"phone":49,"phoneExt":19,"email":50},"Baijun Fang","+86 0371-65587318","fdation@126.com",{"name":52,"role":23,"phone":19,"phoneExt":19,"email":19},"Baijun Fang, Doctor",{"name":54,"role":23,"phone":19,"phoneExt":19,"email":19},"Quande Lin, Doctor",{"facility":56,"status":19,"city":57,"state":58,"zip":19,"country":38,"countryCode":39,"cosmosGeoPoint":59,"geoPoint":63,"contacts":64},"Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","Wuhan","Hubei",{"type":41,"coordinates":60},[61,62],114.26667,30.58333,{"lat":62,"lon":61},[65,69],{"name":66,"role":27,"phone":67,"phoneExt":19,"email":68},"Chunrui Li, Doctor","+86 027-83662640","cunrui5650@126.com",{"name":66,"role":23,"phone":19,"phoneExt":19,"email":19},{"facility":71,"status":19,"city":72,"state":73,"zip":19,"country":38,"countryCode":39,"cosmosGeoPoint":74,"geoPoint":78,"contacts":79},"The Affiliated Hospital of Xuzhou Medical University","Xuzhou","Jiangsu",{"type":41,"coordinates":75},[76,77],117.28386,34.20442,{"lat":77,"lon":76},[80,84],{"name":81,"role":27,"phone":82,"phoneExt":19,"email":83},"Zhiling Yan, Doctor","+86 0516-85806985","Hematology_md@126.com",{"name":81,"role":23,"phone":19,"phoneExt":19,"email":19},{"facility":86,"status":19,"city":87,"state":88,"zip":19,"country":38,"countryCode":39,"cosmosGeoPoint":89,"geoPoint":93,"contacts":94},"The First Affiliated Hospital of Nanchang University","Nanchang","Jiangxi",{"type":41,"coordinates":90},[91,92],115.85306,28.68396,{"lat":92,"lon":91},[95,99],{"name":96,"role":27,"phone":97,"phoneExt":19,"email":98},"Fei Li","+86 0791-88693146","ncyf.lifei@outlook.com",{"name":100,"role":23,"phone":19,"phoneExt":19,"email":19},"Fei Li, Doctor",{"facility":102,"status":19,"city":103,"state":19,"zip":19,"country":38,"countryCode":39,"cosmosGeoPoint":104,"geoPoint":108,"contacts":109},"Beijing GoBroad Boren Hospital","Beijing",{"type":41,"coordinates":105},[106,107],116.39723,39.9075,{"lat":107,"lon":106},[110,114],{"name":111,"role":27,"phone":112,"phoneExt":19,"email":113},"Yajing Zhang","+86 010-63290505","23975701@qq.com",{"name":115,"role":23,"phone":19,"phoneExt":19,"email":19},"Yajing Zhang, Doctor",{"facility":117,"status":19,"city":118,"state":19,"zip":19,"country":38,"countryCode":39,"cosmosGeoPoint":119,"geoPoint":123,"contacts":124},"Institute of Hematology & Blood Diseases Hospital","Tianjin",{"type":41,"coordinates":120},[121,122],117.17667,39.14222,{"lat":122,"lon":121},[125,127],{"name":126,"role":27,"phone":28,"phoneExt":19,"email":29},"Gang An, Doctor",{"name":126,"role":23,"phone":19,"phoneExt":19,"email":19},{"type":129,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR",[131],{"name":132,"class":133},"Nanjing Legend Biotech Co.","INDUSTRY","100623654","early-phase-1-a-clinical-study-to-evaluate-lvivo-tavec400-for-the-treatment-of-relapsedrefractory-multiple-myelomalb2505-0001-100623654",false,"NCT07399444","A Clinical Study to Evaluate LVIVO-TaVec400 for the Treatment of Relapsed\u002FRefractory Multiple Myeloma（LB2505-0001）","A Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of the LVIVO-TaVec400 Product in the Treatment of Relapsed\u002FRefractory Multiple Myeloma","LB2505-0001","Inclusion Criteria:\n\n1. Subjects voluntarily participate in clinical studies; Fully informed of this study and signed informed consent; Informed consent form must be obtained prior to initiation of any study-related tests or procedures that are not part of the standard treatment for the subject's disease; Good compliance and cooperation with follow-up.\n2. Age ≥ 18 years.\n3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n4. Has measurable lesions\n5. Relapsed and\u002For refractory multiple myeloma\n6. Life expectancy≥ 3 months\n7. Clinical laboratory values meet screening visit criteria\n8. Adequate organ function.\n\nExclusion Criteria:\n\n1. Prior antitumor therapy with insufficient washout period ;\n2. Patients who are positive for hepatitis B surface antigen (HBsAg), hepatitis B virus deoxyribonucleic acid (HBV DNA), hepatitis C antibody (HCV-Ab), hepatitis C virus ribonucleic acid (HCV RNA), and human immunodeficiency virus antibody (HIV-Ab).\n3. Those who have experienced life-threatening allergic reactions, hypersensitivity reactions or intolerances to the excipients and related additives of the investigational drug; or those with a previous history of severe allergic reactions (such as hypersensitivity reactions, or those for whom the investigator assesses the need to use glucocorticoids to prevent severe immune-related reactions such as allergic reactions).\n4. Any condition deemed by the investigator as rendering the subject unsuitable for participation in this study.\n5. Also enrolled in other clinical studies.","ALL","18 Years",{"count":145,"type":146},38,"ESTIMATED","INTERVENTIONAL",[149],"EARLY_PHASE1","This is a prospective, single-arm, open-label dose-escalation clinical study to evaluate LVIVO-TaVec400 in the treatment of relapsed\u002Frefractory multiple myeloma.",[152],"Multiple Myeloma (MM)",[154],"Relapsed\u002FRefractory multiple myeloma","NOT_YET_RECRUITING","2026-02-02",{"date":158,"type":159},"2026-02-10","ACTUAL",{"date":161,"type":146},"2026-01-10",{"date":163,"type":146},"2030-05-10",{"name":5,"class":6},6]